The first mRNA influenza vaccine has reached American pharmacies: mFLUSIVA, approved for adults 50 and older — under a traditional approval for ages 50 to 64 and an accelerated approval for 65 and older based on immune-response data, with a confirmatory trial still required — according to reporting on the product’s availability this season.
The evidence behind it comes from a Phase 3 programme of more than 40,000 adults aged 50 and older, in which the vaccine was reported 26.6 percent more effective than a standard-dose comparator. That figure deserves its context, as all relative-effectiveness figures do: it is an improvement on a standard product, not a comparison with the high-dose, recombinant and adjuvanted vaccines preferentially recommended for over-65s in the guidance our companion article describes. Readers in that age group should treat “first mRNA” as a technology milestone and discuss product choice with their clinician, not as a ranking the trial did not test.
The platform is the real news. Messenger-RNA manufacture is egg-free, faster to redirect at new strains, and — in the reporting — already showing the season-to-season adaptability that influenza, the fastest-moving target in routine immunisation, has always demanded. The September surveillance picture is the calm in which to use it: influenza activity remains very low nationally in current reporting, hospitalisations minimal, and the season’s peak — historically December to February, sometimes extending to May — still ahead. Protection takes about two weeks to build; the arithmetic favours October arms over December regrets.
mFLUSIVA joins a shelf that already offers the needle-free nasal option for ages 2 to 49 and cell-based vaccine from six months, under the season’s trivalent formulation. Accelerated approval also carries its obligation in plain sight: the confirmatory effectiveness trial in older adults must complete, and its results can amend the label. Reporting that fact is not hesitation about the product; it is how accelerated approval is supposed to work, in public.
Influenza kills tens of thousands in a hard American season, most of them in the age group this vaccine targets. A 26.6 percent relative improvement, a faster platform, and a public that actually shows up in October would compound into the cheapest mortality reduction available to American medicine this winter. The science has done its part ahead of schedule. The schedule now belongs to the readers. General information only — your clinician’s advice governs your own vaccination.
Related reading:
